Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $930.6 million.

  • Cytokinetics' Cash from Financing Activities rose 9548.64% to $330.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.1 million, marking a year-over-year decrease of 62.07%. This contributed to the annual value of $930.6 million for FY2024, which is 320.49% up from last year.
  • Per Cytokinetics' latest filing, its Cash from Financing Activities stood at $930.6 million for FY2024, which was up 320.49% from $221.3 million recorded in FY2023.
  • Cytokinetics' 5-year Cash from Financing Activities high stood at $930.6 million for FY2024, and its period low was $221.3 million during FY2023.
  • Over the past 3 years, Cytokinetics' median Cash from Financing Activities value was $516.2 million (recorded in 2022), while the average stood at $556.0 million.
  • As far as peak fluctuations go, Cytokinetics' Cash from Financing Activities plummeted by 57.12% in 2023, and later skyrocketed by 320.49% in 2024.
  • Over the past 5 years, Cytokinetics' Cash from Financing Activities (Yearly) stood at $234.1 million in 2020, then spiked by 36.67% to $320.0 million in 2021, then spiked by 61.31% to $516.2 million in 2022, then tumbled by 57.12% to $221.3 million in 2023, then soared by 320.49% to $930.6 million in 2024.